Israel - English - Ministry of Health

neopharm (israel)1996 ltd - hop cones dry extract; valerian root dry extract - film coated tablets - hop cones dry extract 42 mg; valerian root dry extract 187.5 mg - valerian - valerian - herbal medicinal product for problems falling asleep and staying asleep, as well as restless sleep.

Israel - English - Ministry of Health

neopharm (israel)1996 ltd - adalimumab - solution for injection - adalimumab 50 mg/ml - adalimumab - • rheumatoid arthritis: idacio in combination with methotrexate is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. idacio can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. adalimumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.• axial spondyloarthritis:-ankylosing spondylitis (as): idacio is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.-axial spondyloarthritis without radiographic evidence of as: idacio is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as, but with objective signs of inflammation by radiological and/or laboratory tests including mri and serum crp levels, who have had an inadequate response to, or are intolerant to, non-steroidal anti-inflammatory drugs.• psoriatic arthritis: idacio is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti rheumatic drug therapy has been inadequate. adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function.• psoriasis: idacio is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.• hidradenitis suppurativa (hs): idacio is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic hs therapy.• crohn’s disease: idacio is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn’s disease who have had an inadequate response to conventional therapy. idacio is indicated for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab. • ulcerative colitis: idacio is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. • uveitis:idacio is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate.• intestinal behcet's disease: idacio is indicated for the treatment of intestinal behcet’s disease in patients who have had an inadequate response to conventional therapy.

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - maralixibat chloride - solution (oral) - maralixibat chloride 10 mg/ml - maralixibat chloride - livamrli ® is an ileal bile acid transporter (ibat) inhibitor indicated for the treatment of cholestatic pruritus in patients with alagille syndrome (algs) 1 year of age and older.

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - sennae folium - tea - sennae folium 75 % - senna glycosides - senna glycosides - laxative.

Israel - English - Ministry of Health

neopharm (israel)1996 ltd - berotralstat as dihydrochloride - capsules - berotralstat as dihydrochloride 110 mg - berotralstat - orladeyo is indicated for prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - berotralstat as dihydrochloride - capsules - berotralstat as dihydrochloride 150 mg - berotralstat - orladeyotm is indicated for prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older.

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - zoledronic acid as monohydrate - concentrate for solution for infusion - zoledronic acid as monohydrate 4 mg - zoledronic acid - treatment of hypercalcaemia of malignancy. treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors , in conjunction with standard antineoplastic therapy. prostate cancer should have progressed after treatment with at least one hormonal therapy.

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - hawthorn leaf and flower native extract; hop native extract; passion flower howthorn berries (2.8:1) native extract; valerian native extract - dragee - valerian native extract 67.5 mg; hop native extract 29.4 mg; passion flower howthorn berries (2.8:1) native extract 81 mg; hawthorn leaf and flower native extract 81 mg - other hypnotics and sedatives - sedative, anxiety and tension states, insomnia.

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - meropenem as anhydrous - powder for solution for inj/inf - meropenem as anhydrous 1000 mg/vial - meropenem - for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meropenem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - meropenem as anhydrous - powder for solution for inj/inf - meropenem as anhydrous 500 mg/vial - meropenem - for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meropenem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.